Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma
Evaluate the efficacy and safety of tislelizumab in combination with anlotinib in patients with stage III and IV PSC .
Pulmonary Pleomorphic Carcinoma|Immunotherapy|Tislelizumab
DRUG: Tislelizumab in combination with anlotinib
Objective Response Rate, ORR, ORR will be defined as the proportion of participants with a documented, confirmed complete response or partial response per RECIST v1.1., Until the disease progression, an average of 1 year
Progression-free survival, PFS, PFS will be defined as the time from the date of randomization to the date of the first objectively documented tumor progression per RECIST v1.1, or death, whichever occurs first PFS will be defined as the time from the date of randomization to the date of the first objectively documented tumor progression per RECIST v1.1, or death, whichever occurs first PFS will be defined as the time from the date of treatment to the date of the first objectively documented tumor progression per RECIST v1.1, or death, whichever occurs first, rom date of treat until the date of first disease progression or date of death from any cause, whichever came first, assessed up to 2 years|Disease Control Rate, DCR, defined as the proportion of participants whose best overall response (BOR) is complete response, partial response or stable disease as determined by the IRC based on RECIST v1.1 defined as the proportion of participants whose best overall response (BOR) is complete response, partial response or stable disease as determined by the IRC based on RECIST v1.1, Until the disease progression, an average of 1 year|Proportion of adverse events, Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Up to approximately 12 months or end of treatment visit, whichever came first
This is a single-arm, prospective, open phase II clinical study to evaluate the efficacy and safety of tislelizumab in combination with anlotinib in patients with stage III and Stage IV PSC. The primary endpoint of this study was Objective Response Rate (ORR).